Study finds almost no link between fruit and vegetable intake and reduced cancer risk

Could the famous 1990 recommendation from the World Health Organization regarding the number of daily servings of fruits and vegetables to lower one's cancer risk have been wrong? A recent enormous prospective study says … it's likely.

TRIAL DETAILS

An international team of researchers examined data from the European Prospective Investigation into Cancer and Nutrition (EPIC), which followed over 400,000 men and women for an average of 8.7 years. They then applied Cox regression analysis looking for links between lifestyle, diet and the risk of developing cancer.

COHORT

142,605 men
335,873 women

FINDINGS

What they found was a reduced cancer risk linked to:
Increased intake of total fruit and vegetables (3 %)
Increased vegetable intake (2% for women, not for men)
Increased fruit intake (1 %)

COMMENTARY

The authors concluded: "A very small inverse association between intake of total fruits and vegetables and cancer risk was observed in this study. Given the small magnitude of the observed associations, caution should be applied in their interpretation."

In an accompanying editorial, a professor of epidemiology and nutrition at the Harvard School of Public Health noted that these findings merely confirm what previous findings have shown: that fruit and vegetable intake seems to do little or nothing towards lowering one's cancer risk, although the intake might help reduce one's risk of heart disease.

PUBLICATION & SOURCES

These findings were published in the Journal of the National Cancer Institute.

By Ross Bonander

Source: J Natl Cancer Inst

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap